<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400713</article-id><article-id pub-id-type="pmc">PMC12093104</article-id><article-id pub-id-type="publisher-id">1530270</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1530270</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-X<sub>L</sub> and MCL-1</article-title><alt-title alt-title-type="left-running-head">Xu et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2025.1530270" ext-link-type="uri">10.3389/fphar.2025.1530270</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Xu</surname><given-names>Meng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2076466/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hao</surname><given-names>Feng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1602601/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Shuangshuang</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2105062/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Qu</surname><given-names>Zhanning</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2897030/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Junying</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Shuang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2898551/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fang</surname><given-names>Fang</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhao</surname><given-names>Yundong</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2112504/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hu</surname><given-names>Cheng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1796116/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>College of Laboratory Medicine</institution>, <institution>Jilin Medical University</institution>, <addr-line>Jilin City</addr-line>, <addr-line>Jilin</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>School of Medical Technology</institution>, <institution>Beihua University</institution>, <addr-line>Jilin City</addr-line>, <addr-line>Jilin</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Medical Laboratory Department</institution>, <institution>Hepatobiliary Hospital of Jilin Province</institution>, <addr-line>Changchun</addr-line>, <addr-line>Jilin</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Pediatric Hematology</institution>, <institution>Children&#x02019;s Medical Center</institution>, <institution>The First Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <addr-line>Jilin</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Second Affiliated Hospital of Guangdong Medical University</institution>, <addr-line>Guangzhou</addr-line>, <addr-line>Guangdong</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/343937/overview" ext-link-type="uri">Dongwen Lyu</ext-link>, Augusta University, United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/2262623/overview" ext-link-type="uri">Jasper de Boer</ext-link>, Hudson Institute of Medical Research, Australia</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/2605380/overview" ext-link-type="uri">Zhengyu Wang</ext-link>, The University of Texas Health Science Center at San Antonio, United States</p></fn><corresp id="c001">*Correspondence: Fang Fang, <email>jlmmcfang@163.com</email>; Yundong Zhao, <email>18604498530@163.com</email>; Cheng Hu, <email>huchenghq@163.com</email>
</corresp><fn fn-type="equal" id="fn001"><label>
<sup>&#x02020;</sup>
</label><p>These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1530270</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Xu, Hao, Wu, Qu, Li, Chen, Fang, Zhao and Hu.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Xu, Hao, Wu, Qu, Li, Chen, Fang, Zhao and Hu</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Currently, intensive chemotherapy with cytarabine and anthracycline (the &#x0201c;7 + 3&#x0201d; regimen) and hypomethylating agents remains the standard treatment for patients with acute myeloid leukemia (AML). Despite advances in treatment such as targeted therapies, patient outcomes remain unsatisfactory due to adverse drug reactions, susceptibility to drug resistance, and high recurrence rates. Consequently, there is an urgent need to develop safer and more efficacious treatments for AML. In this study, we examined the effects of 20(S)-protopanaxadiol (20(S)-PPD) on AML cells. Our findings indicate that 20(S)-PPD inhibits cell proliferation and induces apoptosis in AML cells. Mechanistically, 20(S)-PPD-induced apoptosis was at least partially dependent on the anti-apoptotic proteins MCL-1 and Bcl-X<sub>L</sub>. Moreover, the downregulation of MCL-1 and Bcl-X<sub>L</sub> by 20(S)-PPD is mediated through the inhibition of transcription and a decrease in protein stability. Additionally, results from virtual molecular docking demonstrated that 20(S)-PPD exhibits lower binding energies with MCL-1 and Bcl-X<sub>L</sub> (&#x02212;7.58 and &#x02212;8.75&#x000a0;kcal/mol, respectively), suggesting that 20(S)-PPD may directly interact with these proteins, thereby accelerating their degradation. Finally, 20(S)-PPD has been shown to synergistically enhance the anti-leukemic activity of venetoclax, a selective Bcl-2 inhibitor, in AML cells. The current study suggests that the continued development of 20(S)-PPD as a therapeutic agent for AML would be advantageous.</p></abstract><kwd-group><kwd>acute myeloid leukemia</kwd><kwd>20(S)-protopanaxadiol</kwd><kwd>MCL-1</kwd><kwd>Bcl-X<sub>L</sub>
</kwd><kwd>apoptosis</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. The present study was supported by The Science and Technology Development Plan Project of Jilin Province (202512JC010176508, 20220101338JC, and YDZJ202401085ZYTS) and Key R&#x00026;D Project of Science and Technology Department of Jilin Provincial (20230202059NC).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pharmacology of Anti-Cancer Drugs</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Acute myeloid leukemia (AML) occurs when immature myeloid progenitor cells accumulate in the bone marrow and peripheral blood due to impaired clonal proliferation and differentiation (<xref rid="B49" ref-type="bibr">Siveen et al., 2017</xref>). According to estimates, AML has a 5-year overall survival rate of only 30% and is considered the most lethal subtype of acute leukemia (<xref rid="B17" ref-type="bibr">Khwaja et al., 2016</xref>; <xref rid="B19" ref-type="bibr">Lai et al., 2019</xref>; <xref rid="B46" ref-type="bibr">Shimony et al., 2023</xref>). The intensive induction chemotherapy regimen, known as the &#x0201c;7 + 3 regimen&#x0201d; and consisting of cytarabine and anthracyclines, has been a mainstay in the therapeutic management of AML since 1973 (<xref rid="B20" ref-type="bibr">Lichtman, 2013</xref>). However, this intensive chemotherapy is not suitable for elderly patients or those with adverse risk cytogenetics or comorbidities. Although pediatric AML patients have fewer comorbidities and can tolerate intensive treatment better than adults, the overall survival rate (approximately 65%) is still not satisfactory. Advances in molecular technologies have revealed numerous molecular abnormalities that contribute to AML pathogenesis (<xref rid="B19" ref-type="bibr">Lai et al., 2019</xref>; <xref rid="B29" ref-type="bibr">Nwosu et al., 2024</xref>). Consequently, targeted therapies have been developed and recently approved for the treatment of AML, including agents that target FMS-like tyrosine kinase 3 (FLT3), isocitrate dehydrogenase (IDH), and Bcl-2 (<xref rid="B45" ref-type="bibr">Shimada, 2019</xref>). Nonetheless, new clinical challenges have emerged due to the development of resistance to these agents (<xref rid="B37" ref-type="bibr">Qi et al., 2015</xref>; <xref rid="B54" ref-type="bibr">Wei and Roberts, 2023</xref>). Therefore, it is essential to develop more effective or adjuvant therapies for AML with urgency.</p><p>Over recent decades, numerous active molecules derived from traditional Chinese medicinal plants have shown efficacy in the prevention and treatment of cancer, exhibiting lower toxicity and fewer side effects, thereby representing a promising therapeutic option (<xref rid="B59" ref-type="bibr">Zhang et al., 2021</xref>). Ginsenosides, a class of triterpenoid saponins extracted from ginseng roots, constitute the primary pharmacologically active constituents of ginseng (<xref rid="B44" ref-type="bibr">Shi et al., 2019</xref>). Saponins in ginseng are primarily classified into three types: dammarane-type saponins (such as protopanaxadiol and protopanaxatriol), ocotillol-type saponins, and oleanane-type saponins, with the dammarane type being the most prevalent (<xref rid="B56" ref-type="bibr">Wong et al., 2015</xref>; <xref rid="B24" ref-type="bibr">Liu et al., 2020</xref>).</p><p>20(S)-protopanaxadiol (20(S)-PPD) is produced through acid hydrolysis and the action of intestinal bacteria via a series of de-glycosylation processes after oral administration of ginsenosides. This transformation enhances their bioavailability and facilitates absorption by the human body (<xref rid="B15" ref-type="bibr">Jo et al., 2021</xref>). Studies have revealed that 20(S)-PPD is an effective antitumor agent against various solid tumors, demonstrating its efficacy both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="B62" ref-type="bibr">Zhu et al., 2011</xref>; <xref rid="B61" ref-type="bibr">Zhang et al., 2013</xref>; <xref rid="B2" ref-type="bibr">Ben-Eltriki et al., 2016</xref>; <xref rid="B57" ref-type="bibr">Zhang et al., 2018</xref>; <xref rid="B33" ref-type="bibr">Peng et al., 2019</xref>; <xref rid="B25" ref-type="bibr">Lu et al., 2020</xref>; <xref rid="B58" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B10" ref-type="bibr">Fu et al., 2022</xref>; <xref rid="B50" ref-type="bibr">Song et al., 2023</xref>). Given the paucity of data on AML, we conducted an investigation into the cytotoxic effects and underlying mechanisms of 20(S)-PPD on AML cells. Here, we show that 20(S)-PPD inhibits cell proliferation and induces apoptosis in AML cells. Bcl-X<sub>L</sub> and MCL-1 play crucial roles in 20(S)-PPD-induced apoptosis. Furthermore, the combination of 20(S)-PPD and venetoclax exhibited a synergistic effect in inhibiting proliferation and inducing apoptosis in AML cells.</p></sec><sec sec-type="materials|methods" id="s2"><title>2 Materials and methods</title><sec id="s2-1"><title>2.1 Drugs</title><p>20(S)-protopanaxadiol (20(S)-PPD), venetoclax, A-1155463 Dihydrochloride, A-1210477, MG132, and cycloheximide were obtained from the Selleck Chemical (Houston, United States).</p></sec><sec id="s2-2"><title>2.2 Cells lines and culture</title><p>THP-1 and MOLM-13 cells were provided by Procell Life Science (Wuhan, China), while MV4-11 cells were obtained from ATCC (Manassas, VA, United States). The cell lines were maintained at 37&#x000b0;C in an incubator with 5% CO<sub>2</sub> and RPMI-1640 medium supplemented with 100 U/mL penicillin, 100&#x000a0;&#x003bc;g/mL streptomycin, and 10% fetal bovine serum (FBS, CLARK Bioscience, United States). The same conditions were used for THP-1 shRNA knockdown cell lines, but puromycin was added at 2&#x000a0;&#x003bc;g/mL.</p></sec><sec id="s2-3"><title>2.3 CCK-8 assays</title><p>The Cell Counting Kit-8 (CCK-8; BioSS, Beijing, China) was used to assess cell viability. Following a 48-h exposure of AML cells to varying concentrations of 20(S)-PPD, 10&#x000a0;&#x003bc;L of the CCK-8 reagent was added to each well of a microplate. Subsequently, the cells were incubated for an additional 2&#x000a0;h to allow for the colorimetric reaction to develop. The optical density (OD) at 450&#x000a0;nm of the cells was measured using a microplate reader (BMG LABTECH, GmbH, Germany).</p></sec><sec id="s2-4"><title>2.4 Annexin V/propidium iodide staining</title><p>The Annexin V-FITC/propidium iodide (PI) staining (Bestbio, Shanghai, China) was used to determine cell apoptosis. Briefly, a final concentration of 0, 20, 40, 60&#x000a0;&#x003bc;M of 20(S)-PPD was applied to cells plated into 24-well plates. After treating the cells with 20(S)-PPD at different concentrations, a 5-min centrifugation at 1,500&#x000a0;rpm was performed. The cells were then resuspended in 50&#x000a0;&#x003bc;L of 1&#x000d7; binding buffer, and 3&#x000a0;&#x003bc;L of propidium iodide (PI) and 6&#x000a0;&#x003bc;L of Annexin V-FITC solution were added. The mixtures were incubated in the dark for 15&#x000a0;min at room temperature. Flow cytometry analysis (Beckman, United States) was performed after adding 400&#x000a0;&#x003bc;L of binding buffer to each tube. Based on a typical experiment, the average percentages of Annexin V+/PI- (early apoptosis) and Annexin V+/PI+ (late apoptosis or dead cells) were determined.</p></sec><sec id="s2-5"><title>2.5 Mitochondria membrane potential assay</title><p>The JC-10 staining kit (Bestbio, Shanghai, China) was used to assessed mitochondrial membrane potential (MMP). Briefly, AML cells were exposed to 20(S)-PPD at final concentrations of 0, 20, 40, and 60&#x000a0;&#x003bc;M for 8&#x000a0;h. Following treatment, the cells were washed twice with phosphate-buffered saline (PBS) and subsequently centrifuged at 1,500&#x000a0;rpm for 5&#x000a0;min to collect the cells. The cells were then resuspended in 500&#x000a0;&#x003bc;L of JC-10 staining working solution, prepared according to the manufacturer&#x02019;s instructions, and incubated at 37&#x000b0;C with 5% CO<sub>2</sub> for 30&#x000a0;min. A reduction in MMP is recognized as a hallmark event in the early stages of apoptosis. When the MMP is high, JC-10 preferentially accumulates within the mitochondrial matrix, resulting in the formation of red fluorescence. In contrast, a low MMP leads to the dissociation of JC-10 into monomers, which emit green fluorescence. Subsequently, flow cytometry analysis was conducted to quantify the fluorescence intensity at excitation/emission wavelengths of 510&#x000a0;nm/570&#x000a0;nm for red fluorescence and 488&#x000a0;nm/520&#x000a0;nm for green fluorescence. The ratio of red to green fluorescence intensity serves as an indicator of the cellular MMP, allowing for normalization of the data.</p></sec><sec id="s2-6"><title>2.6 Western blot analysis</title><p>After treating AML cells with 20(S)-PPD at final concentrations ranging from 0 to 60&#x000a0;&#x003bc;M for 8&#x000a0;h, Western blot was performed to detect PARP cleavage and apoptosis-associated proteins. Incubation of cells at 37&#x000b0;C resulted in their harvesting and lysis in ultrasonic lysates containing inhibitors of proteases and phosphatases. The cells were then ultrasonically broken using an ultrasonic crusher with 130&#x000a0;W power, ultrasonication for 1&#x000a0;s, stopping for 1&#x000a0;s, and a total ultrasonication time of 1&#x000a0;min. After centrifuging the total lysate for 10&#x000a0;min at 12,000&#x000a0;rpm, the supernatants were analyzed using a BCA protein assay kit (Thermo Fisher Scientific, United States). We added 20&#x000a0;&#x003bc;g of cell extract to a polyacrylamide-SDS gel containing 5% concentrated gel and 10% separating gel. Once the gels were electrophoretically transferred to PVDF membranes, the membranes were blocked with 5% skim milk for 1&#x000a0;h at room temperature. The membrane, after transfer, was incubated overnight at 4&#x000b0;C with either anti-Bcl-2 family (selleck) or anti-PARP (proteintech) antibodies, both diluted to 1:1,000. After 1&#x000a0;h of incubation with HRP-conjugated secondary antibodies, chemiluminescence (Fine-Do X3, Bioscience, Beijing, China) was used to visualize protein bands using the HRP reaction with its substrates.</p></sec><sec id="s2-7"><title>2.7 Real-time quantitative PCR analysis</title><p>Real-time quantitative PCR (qRT-PCR) was used to detect mRNA expression following an 8-h treatment with 20(S)-PPD at concentrations of 0, 20, 40, and 60&#x000a0;&#x003bc;M. Total RNA was isolated using the Total RNA Extraction Kit (Solarbio, China), and cDNA was synthesized using the SureScriptTM First-Strand cDNA Synthesis Kit (GeneCopoeia, China). The MonAmpTM qPCR Kit (Monad Biology, China) and 7,500 Real-Time PCR System (Applied Biosystems, United States) were used in a 20&#x000a0;&#x003bc;L total volume for RT-qPCR. Using the comparative Ct method with &#x003b2;-actin as the housekeeping gene, the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> values were calculated to evaluate mRNA expression levels. The primers used for amplification were as follows: MCL-1:5&#x02032;-GGAGTTGGTCGGGGAATCTG-3&#x02032; and 5&#x02032;-CTC&#x0200b;CCG&#x0200b;AAG&#x0200b;GTA&#x0200b;CCG&#x0200b;AGA&#x0200b;GA-3&#x02032;; Bcl-X<sub>L</sub>: 5&#x02032;-AAC&#x0200b;TCT&#x0200b;TCC&#x0200b;GGG&#x0200b;ATG&#x0200b;GGG&#x0200b;TA-3&#x02032; and 5&#x02032;-CTG&#x0200b;CGA&#x0200b;TCC&#x0200b;GAC&#x0200b;TCA&#x0200b;CCA&#x0200b;AT-3&#x02032;; &#x003b2;-actin: 5&#x02032; TCC&#x0200b;TCC&#x0200b;CTG&#x0200b;GAG&#x0200b;AAG&#x0200b;AGC&#x0200b;TAC-3&#x02032; and 5&#x02032;-TCC&#x0200b;TGC&#x0200b;TTG&#x0200b;CTG&#x0200b;ATC&#x0200b;CAC&#x0200b;AT-3&#x02032;.</p></sec><sec id="s2-8"><title>2.8 Production of lentivirus particles and infection of THP-1 cells</title><p>Sigma-Aldrich provided the non-target control vector and Bax-/Bak-shRNA constructs, while Dharmacon supplied the Bcl-X<sub>L</sub> and MCL-1 open reading frame (ORF) constructs. Lentivirus production was achieved by co-transfecting HEK293T cells with the lentiviral shRNA, pMD-VSV-G, and delta 8.2 plasmids. Viral supernatants were harvested 48&#x000a0;h post-co-transfection, and 1&#x000a0;mL of viral supernatant mixed with 4&#x000a0;&#x003bc;g/mL polybrene (Sigma-Aldrich) was added to THP-1 cells to evaluate infection efficiency. Puromycin at a concentration of 2&#x000a0;&#x003bc;g/mL was used to screen for shRNA lentiviral gene silencing cell lines.</p></sec><sec id="s2-9"><title>2.9 Molecular docking</title><p>Using the PubChem database (<ext-link xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link>), we predicted the 3D structure and binding activity of 20(S)-PPD to the relevant targets. The PDB database (<ext-link xlink:href="https://www.pdb.org/" ext-link-type="uri">https://www.pdb.org/</ext-link>) was used to download the protein structures of the target proteins and remove ligands and non-protein molecules. Before docking could begin, all hydrogens needed to be added to small-molecule drugs and protein structures. With the help of Pymol software, we visualized the docking results using Auto Dock 4. In docking analyses, the model with the smallest G score was regarded as the most appropriate. Docking of 20(S)-PPD with target proteins required binding energies of at least &#x02212;5.0&#x000a0;kcal/mol. Only results with these energies were accepted.</p></sec><sec id="s2-10"><title>2.10 Statistical analysis</title><p>Statistical analysis was conducted using GraphPad Prism 9.0. Values are presented as mean &#x000b1; SEM (error bar). Statistical significance was determined with an unpaired two-tailed t-test. The significance threshold was set at P &#x02264; 0.05 for the column graphs. The IC<sub>50</sub> was calculated in non-linear regression by selecting the log (inhibitor) vs normalized response - Variable slope model in the Dose-response-Inhibition category.</p></sec></sec><sec sec-type="results" id="s3"><title>3 Results</title><sec id="s3-1"><title>3.1 20(S)-PPD treatment inhibited proliferation and induced apoptosis in AML cells</title><p>AML cells were treated with concentrations ranging from 0 to 60&#x000a0;&#x003bc;M of 20(S)-PPD for 48&#x000a0;h to investigate its anti-proliferative effect. The CCK-8 assay demonstrated that 20(S)-PPD inhibited cell proliferation in a dose-dependent manner (<xref rid="F1" ref-type="fig">Figure 1A</xref>). The IC<sub>50</sub> values of 20(S)-PPD for MOLM-13, THP-1, and MV4-11 cells were 29.5 &#x000b1; 1.4&#x000a0;&#x003bc;M, 44.5 &#x000b1; 1.5&#x000a0;&#x003bc;M, and 32.5 &#x000b1; 1.9&#x000a0;&#x003bc;M, respectively (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Further investigation using Annexin V/PI staining and flow cytometry analysis showed that all three tested AML cell lines responded positively to 20(S)-PPD treatment for 8&#x000a0;h, as measured by Annexin V-positive percentage and PARP cleavage (<xref rid="F1" ref-type="fig">Figures 1C, D</xref>). Considering that the decrease in MMP is a hallmark event of early apoptosis, JC-10 staining was performed after treating AML cells with 20(S)-PPD for 8&#x000a0;h to assess the MMP. The results in <xref rid="F1" ref-type="fig">Figure 1E</xref> indicate that 20(S)-PPD reduced MMP in a dose-dependent manner in all tested AML cells. These results demonstrate that AML cells undergo apoptosis in response to 20(S)-PPD. A varying concentration of 20(S)-PPD was then administered for 8&#x000a0;h to peripheral blood mononuclear cells (PBMCs) from healthy donors to evaluate its effect on normal cells. Normal PBMCs treated with 20(S)-PPD did not exhibit an increased percentage of Annexin V-positive cells (<xref rid="F1" ref-type="fig">Figure 1F</xref>), suggesting that 20(S)-PPD may not be toxic to them.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>20(S)-PPD treatment inhibited proliferation and induced apoptosis in AML cells. <bold>(A)</bold> CCK-8 assays were performed on 96-well plates containing 0&#x02013;60&#x000a0;&#x003bc;M 20(S)-PPD for 48&#x000a0;h, with 100% viable cells considered in the vehicle control well. Averaging three duplicate experiments (with standard errors) was used to determine the data. ***P &#x0003c; 0 0.001 compared to the vehicle control. <bold>(B)</bold> Based on three independent experiments, the IC<sub>50</sub> values of 20(S)-PPD were calculated and graphed. <bold>(C)</bold> Annexin V/PI staining and flow cytometry analysis were performed on MOLM-13, THP-1 and MV4-11 cells after 0&#x02013;60&#x000a0;&#x003bc;M 20(S)-PPD treatment for 2, 4, and 8&#x000a0;h. From a representative experiment, apoptosis data is presented as the means of triplicates&#x000b1;standard errors. **P &#x0003c; 0.01; ***P &#x0003c; 0.001 compared to the vehicle control. <bold>(D)</bold> Antibodies targeting cleaved PARP were utilized in Western blot analysis of complete cell lysates. <bold>(E)</bold> JC-10 staining were performed to determine MMP in AML cells after 0&#x02013;60&#x000a0;&#x003bc;M 20(S)-PPD treatment for 8&#x000a0;h. From a representative experiment, apoptosis data is presented as the means of triplicates&#x000b1;standard errors. *P &#x0003c; 0.05; ***P &#x0003c; 0.001 compared to the vehicle control. <bold>(F)</bold> Normal peripheral blood mononuclear cells (PBMCs) were treated with 0&#x02013;60&#x000a0;&#x003bc;M 20(S)-PPD for 8&#x000a0;h and stained with annexin V-FITC/PI. <bold>(G, H)</bold> THP-1 cells were exposed to NTC-, Bax-, or Bak-shRNA lentivirus for 4&#x02013;6&#x000a0;h, followed by washing and a 48-h culture in new media before being treated with 20(S)-PPD. The reduction in Bax or Bak expression was confirmed through Western blot analysis <bold>(G)</bold>. 20(S)-PPD treatment of NTC-shRNA, Bax-shRNA/Bak-shRNA knockdown cells were analyzed by flow cytometry <bold>(H)</bold>. **P &#x0003c; 0.01; ***P &#x0003c; 0.001 compared to the no drug treatment control, while ###P &#x0003c; 0.001 compared to 20(S)-PPD-treated NTC-shRNA cells.</p></caption><graphic xlink:href="fphar-16-1530270-g001" position="float"/></fig><p>In the mitochondrial apoptotic pathway, Bcl-2 (B Cell Lymphoma 2) proteins Bax and Bak, central effectors of mitochondrial apoptosis, play key roles. When apoptotic signals are initiated, both Bax and Bak insert into the outer mitochondrial membrane, forming oligomers that alter the permeability of the mitochondrial membrane. This change allows the release of cytochrome c, leading to the activation of caspases and ultimately resulting in apoptosis (<xref rid="B43" ref-type="bibr">Shamas-Din et al., 2013</xref>). With lentiviral vectors containing Bax/Bak shRNA, we engineered THP-1 cells with a double knockdown of Bax and Bak to determine whether 20(S)-PPD induces apoptosis via the intrinsic/mitochondrial apoptotic pathway. Western blot analysis revealed that, in comparison to the sh-NTC (non-target control), the protein expressions of Bax and Bak were evidently reduced in the Bax/Bak dual knockdown THP-1 cells (<xref rid="F1" ref-type="fig">Figure 1G</xref>). Dual knockdown significantly mitigated 20(S)-PPD-induced apoptosis on AML cells (<xref rid="F1" ref-type="fig">Figure 1H</xref>), indicating that mitochondrial/intrinsic pathways are involved in 20(S)-PPD-induced apoptosis. Based on the data presented in <xref rid="F1" ref-type="fig">Figure 1</xref>, 20(S)-PPD appears to inhibit proliferation and induce apoptosis in AML cell lines, but not in normal PBMCs. The apoptosis induced by 20(S)-PPD appears to be mediated, at least in part, through the intrinsic/mitochondrial apoptotic pathway.</p></sec><sec id="s3-2"><title>3.2 20(S)-PPD treatment downregulated the expression levels of Bcl-X<sub>L</sub> and MCL-1 in AML cells</title><p>It is well established that the Bcl-2 family proteins are critical regulators of intrinsic/mitochondrial apoptosis, functioning as both promoters and inhibitors of cell death (<xref rid="B7" ref-type="bibr">Czabotar and Garcia-Saez, 2023</xref>). Given that 20(S)-PPD-induced apoptosis involves the intrinsic/mitochondrial pathway, we examined the levels of the anti-apoptotic proteins Bcl-2, Bcl-X<sub>L</sub>, and MCL-1 and the pro-apoptotic proteins Bax, Bak, and Bim using Western blotting in AML cells following increasing concentrations of 20(S)-PPD for 8&#x000a0;h. The data presented in <xref rid="F2" ref-type="fig">Figure 2</xref> indicate that treatment with 20(S)-PPD resulted in a reduction of MCL-1 and Bcl-X<sub>L</sub> levels, while the expression of Bcl-2, Bfl-1, Bax, and Bak remained unaffected across all three tested AML cell lines. Additionally, the expression of Bim exhibited a slight increase in THP-1 and MV4-11 cells, but remained unchanged in MOLM-13 cells following 20(S)-PPD treatment. These findings suggest that the downregulation of MCL-1 and Bcl-X<sub>L</sub> may play a role in mediating 20(S)-PPD-induced apoptosis in AML cells.</p><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>20(S)-PPD treatment downregulated the expression of anti-apoptotic proteins MCL-1 and Bcl-X<sub>L</sub> in AML cells. After treating MOLM-13, THP-1 and MV4-11 cells for 8&#x000a0;h with 0&#x02013;60&#x000a0;&#x003bc;M 20(S)-PPD, whole cell lysates were analyzed by Western blotting. Densitometry measurements are shown below the corresponding blots, normalized to &#x003b2;-actin and compared to the vehicle control group.</p></caption><graphic xlink:href="fphar-16-1530270-g002" position="float"/></fig></sec><sec id="s3-3"><title>3.3 Bcl-X<sub>L</sub> and MCL-1 play roles in 20(S)-PPD-induced apoptosis</title><p>Using lentivirus containing ORFs of Bcl-X<sub>L</sub> and MCL-1, we successfully overexpressed Bcl-X<sub>L</sub> and MCL-1 in THP-1 cells to study their involvement in 20(S)-PPD-induced apoptosis (<xref rid="F3" ref-type="fig">Figure 3A</xref>). <xref rid="F3" ref-type="fig">Figure 3B</xref> shows that the overexpression of Bcl-X<sub>L</sub> and MCL-1 partially mitigated 20(S)-PPD-induced apoptosis as determined by annexin V/PI staining and flow cytometry.</p><fig position="float" id="F3"><label>FIGURE 3</label><caption><p>Bcl-X<sub>L</sub> and MCL-1 play important roles in 20(S)-PPD-induced apoptosis. <bold>(A, B)</bold> Infection of THP-1 cells with Precision LentiORF Bcl-X<sub>L</sub>, MCL-1, and mock (negative control) lentivirus for 4&#x02013;6&#x000a0;h was followed by washing and incubation in fresh media for 48&#x000a0;h. A whole cell lysate was subjected to Western blot analysis with anti-Bcl-X<sub>L</sub> or anti-MCL-1 antibodies <bold>(A)</bold> and compared with a mock group to determine density. OE, overexpression. After treating the cells with 0&#x02013;60&#x000a0;&#x003bc;M 20(S)-PPD for 8&#x000a0;h, Annexin V/PI staining and flow cytometry analyses were performed <bold>(B)</bold>. ***P &#x0003c; 0.001 compared to no drug treatment control, while ###P &#x0003c; 0.001, compared to 20(S)-PPD treated mock group. <bold>(C, D)</bold> Using MOLM-13 cells <bold>(C)</bold> and THP-1 cells <bold>(D)</bold>, we treated them with 20(S)-PPD alone or combined with theA-1210477 (MCL-1 inhibitor) or A-1155463 Dihydrochloride (Bcl-X<sub>L</sub> inhibitor) for 24&#x000a0;h. After that, we performed a CCK-8 assay and calculated IC<sub>50</sub> values. The axes show the IC<sub>50</sub> values for each inhibitor. There is a solid line to indicate additive effects, while the points show concentrations that inhibit proliferation by 50%. A synergistic point is below the line, whereas an antagonistic point is above it. <bold>(E, F)</bold> MOLM-13 cells <bold>(E)</bold> and THP-1 cells <bold>(F)</bold> were treated with 20(S)-PPD alone or in combination with the A-1210477 or A-1155463 Dihydrochloride for 8&#x000a0;h and then stained with Annexin V/PI staining and flow cytometry analyses. ***P &#x0003c; 0.001 compared to the no drug treatment control, while ###P &#x0003c; 0.001 compared to 20(S)-PPD-treated group.</p></caption><graphic xlink:href="fphar-16-1530270-g003" position="float"/></fig><p>A-1210477 (MCL-1 inhibitor) and A-1155463 Dihydrochloride (Bcl-X<sub>L</sub> inhibitor), respectively, were co-treated with 20(S)-PPD to further study their roles in 20(S)-PPD-induced apoptosis. As demonstrated in <xref rid="F3" ref-type="fig">Figures 3C, D</xref>, the CCK-8 assay revealed that the inhibitors of MCL-1 or Bcl-X<sub>L</sub> synergistically inhibited the proliferation of THP-1 and MOLM-13 cells when combined with 20(S)-PPD. Similarly, the MCL-1 or Bcl-X<sub>L</sub> inhibitors significantly enhanced 20(S)-PPD-induced apoptosis in the two AML cell lines, as illustrated in <xref rid="F3" ref-type="fig">Figures 3E, F</xref>. Collectively, these results indicate that 20(S)-PPD induces apoptosis in AML cells by downregulating the levels of MCL-1 or Bcl-X<sub>L</sub>, as shown in <xref rid="F3" ref-type="fig">Figure 3</xref>.</p></sec><sec id="s3-4"><title>3.4 20(S)-PPD treatment reduced the mRNA level and protein stability of Bcl-X<sub>L</sub> and MCL-1</title><p>20(S)-PPD was treated for 8&#x000a0;h in THP-1 and MOLM-13 cells in order to explore the potential molecular mechanisms by which it regulates Bcl-X<sub>L</sub> and MCL-1 expression. qRT-PCR was performed with actin as the reference gene, and the data were subsequently normalized to these baseline values. The relative quantification was exhibited by calculating the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> values. A dose-dependent decrease in Bcl-X<sub>L</sub> and MCL-1 mRNA expression was observed in MOLM-13 and THP-1 cells treated with 20(S)-PPD, as shown in <xref rid="F4" ref-type="fig">Figure 4A</xref>.</p><fig position="float" id="F4"><label>FIGURE 4</label><caption><p>20(S)-PPD treatment decreased the mRNA and protein stability of Bcl-X<sub>L</sub> and MCL-1. <bold>(A)</bold> We isolated RNA from MOLM-13 and THP-1 cells and detected Bcl-X<sub>L</sub> and MCL-1 transcript levels using qRT-PCR after treatment with 0&#x02013;60&#x000a0;&#x003bc;M 20(S)-PPD for 8&#x000a0;h. The fold change normalized to &#x003b2;-actin. Data are represented as means &#x000b1; SD of at least triplicate measurements. *P &#x0003c; 0.05; ***P &#x0003c; 0.001 compared to the no drug treatment control. <bold>(B, C)</bold> MOLM-13 cells <bold>(B)</bold> and THP-1 cells <bold>(C)</bold> were treated with 40&#x000a0;&#x003bc;M 20(S)-PPD for 8&#x000a0;h, and then washed away the drug and added 10&#x000a0;&#x003bc;g/mL of Cycloheximide (CHX) to inhibit protein synthesis. Western blotting was probed with indicated antibodies. The density measurements for the corresponding blots are shown below, normalized to &#x003b2;-actin. Representative western blots are shown on the left, while half-life time shown on the right. *P &#x0003c; 0.05; **P &#x0003c; 0.01 compared to the no drug treatment control. <bold>(D, E)</bold> The graph of virtual molecular docking. 20(S)-PPD interacts directly with MCL-1 <bold>(D)</bold> and Bcl-X<sub>L</sub>
<bold>(E)</bold>. <bold>(F)</bold> MOLM-13 and THP-1 cells were exposed to 40&#x000a0;&#x003bc;M 20(S)-PPD for 8&#x000a0;h, either alone or in combination with 300&#x000a0;nM MG132, for 24&#x000a0;h. Subsequently, Western blotting was conducted to analyze the levels of Bcl-X<sub>L</sub> and MCL-1. The resulting band densities were compared to those of the vehicle control and normalized to &#x003b2;-actin.</p></caption><graphic xlink:href="fphar-16-1530270-g004" position="float"/></fig><p>Subsequently, 20(S)-PPD was investigated for its effect on Bcl-X<sub>L</sub> and MCL-1 post-transcriptionally. After treating THP-1 and MOLM-13 cells for 8&#x000a0;h with 20(S)-PPD, 10&#x000a0;&#x003bc;g/mL of Cycloheximide (CHX) was used to inhibit the synthesis of proteins. The expressions of Bcl-X<sub>L</sub> and MCL-1 were then measured at various time points using Western blotting to determine the protein degradation rate and half-life. MCL-1 has been demonstrated to be an unstable protein with a half-life ranging from 1.5 to 4&#x000a0;h, in contrast to Bcl-X<sub>L</sub>, which exhibits stability with a half-life of approximately 20&#x000a0;h (<xref rid="B41" ref-type="bibr">Rooswinkel et al., 2014</xref>). Our data indicated that the half-life of MCL-1 in MOLM-13 cells was 131.5 &#x000b1; 21.1&#x000a0;min, which decreased to 87.7 &#x000b1; 17&#x000a0;min following the addition of 20(S)-PPD. Similarly, in THP-1 cells, the half-life of MCL-1 was 133.3 &#x000b1; 5&#x000a0;min, which further decreased to 73.4 &#x000b1; 9.6&#x000a0;min after the addition of 20(S)-PPD (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Additionally, the half-life of Bcl-X<sub>L</sub> protein was reduced from 48.2 &#x000b1; 6.6&#x000a0;h to 26.7 &#x000b1; 5.8&#x000a0;h in MOLM-13 cells and from 36.1 &#x000b1; 4.6&#x000a0;h to 21.7 &#x000b1; 2.3&#x000a0;h in THP-1 cells (<xref rid="F4" ref-type="fig">Figure 4C</xref>). These results indicate that 20(S)-PPD accelerated the Bcl-X<sub>L</sub> and MCL-1 protein degradation.</p><p>To better understand how 20(S)-PPD facilitates the degradation of Bcl-X<sub>L</sub> and MCL-1, a virtual molecular docking was conducted using AutoDock 4 software. The docking results revealed that 20(S)-PPD directly interacts with either the MCL-1 or Bcl-X<sub>L</sub> proteins, forming hydrogen bonds with ARG-263 on MCL-1, or with PRO-116 on Bcl-X<sub>L</sub> (<xref rid="F4" ref-type="fig">Figures 4D, E</xref>). Additionally, 20(S)-PPD exhibited lower Gibbs free energy values of &#x02212;8.75&#x000a0;kcal/mol and &#x02212;7.58&#x000a0;kcal/mol for binding to Bcl-X<sub>L</sub> and MCL-1, respectively (<xref rid="T1" ref-type="table">Table 1</xref>). These findings suggest that 20(S)-PPD has a strong binding affinity for both proteins. To further elucidate the role of the proteasome in the degradation of Bcl-X<sub>L</sub> and MCL-1 induced by 20(S)-PPD, we examined the impact of the proteasome inhibitor MG132 on the downregulation of these proteins by 20(S)-PPD. As depicted in <xref rid="F4" ref-type="fig">Figure 4F</xref>, the addition of MG132 significantly mitigated the downregulation of Bcl-X<sub>L</sub> and MCL-1 by 20(S)-PPD. Collectively, 20(S)-PPD may downregulate MCL-1 or Bcl-X<sub>L</sub> protein levels by inhibiting transcription and reducing protein stability.</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>Docking binding energy of 20(S)-PPD to target proteins.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Protein names</th><th align="center" rowspan="1" colspan="1">Protein ID</th><th align="center" rowspan="1" colspan="1">Docking binding energy/kcal.mol<sup>&#x02212;1</sup>
</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">MCL-1</td><td align="center" rowspan="1" colspan="1">3WIY</td><td align="center" rowspan="1" colspan="1">&#x02212;7.58</td></tr><tr><td align="center" rowspan="1" colspan="1">Bcl-X<sub>L</sub>
</td><td align="center" rowspan="1" colspan="1">3WIZ</td><td align="center" rowspan="1" colspan="1">&#x02212;8.75</td></tr></tbody></table></table-wrap></sec><sec id="s3-5"><title>3.5 20(S)-PPD enhanced the anti-leukemic effect of venetoclax on AML cells</title><p>Venetoclax is a selective and potent oral Bcl-2 inhibitor (<xref rid="B11" ref-type="bibr">Guerra et al., 2019</xref>). Venetoclax has been used as monotherapy in patients with relapsed/refractory AML but has demonstrated only modest efficacy with an overall response rate (ORR) of 38% (<xref rid="B22" ref-type="bibr">Liu, 2021</xref>; <xref rid="B30" ref-type="bibr">Ong et al., 2022</xref>). It appears that AML patients have both intrinsic and acquired resistance to venetoclax, resulting in this low ORR. Indeed, due to venetoclax&#x02019;s specific targeting of Bcl-2, tumor cells may shift their dependency to other anti-apoptotic proteins such as Bcl-X<sub>L</sub>, MCL-1 and Bfl-1 for survival (<xref rid="B47" ref-type="bibr">Shimony et al., 2022</xref>). Consequently, this study aims to investigate whether 20(S)-PPD could enhance venetoclax&#x02019;s sensitivity in treating AML. The CCK-8 assay revealed that the combination of 20(S)-PPD and venetoclax synergistically inhibited THP-1 and MOLM-13 cell proliferation (<xref rid="F5" ref-type="fig">Figure 5A</xref>). Further analysis using Annexin V-FITC/PI staining and flow cytometry indicated that 20(S)-PPD significantly augmented venetoclax-induced apoptosis in THP-1 and MOLM-13 cells (<xref rid="F5" ref-type="fig">Figure 5B</xref>). Additionally, treatment with venetoclax alone (1.25&#x000a0;&#x003bc;M) or in combination with 20(S)-PPD slightly increased the percent of Annexin V-positive cells. However, compared to treatment with venetoclax alone, the combination did not significantly further increase the percent of Annexin V-positive cells (p &#x0003e; 0.05), suggesting that the combination of venetoclax and 20(S)-PPD does not introduce additional toxicity (<xref rid="F5" ref-type="fig">Figure 5C</xref>). Mechanistically, we found that compared to treatment with PPD alone, the combination further downregulated Bcl-X<sub>L</sub> and MCL-l, although the level of Bcl-2 remained unchanged (<xref rid="F5" ref-type="fig">Figure 5D</xref>). Collectively, these findings indicate that 20(S)-PPD potentiates the anti-leukemic efficacy of venetoclax in AML cells.</p><fig position="float" id="F5"><label>FIGURE 5</label><caption><p>20(S)-PPD enhanced the anti-leukemic effect of venetoclax on AML cells <bold>(A)</bold> MOLM-13 cells (panel left) and THP-1 cells (panel right) were treated with 20(S)-PPD alone or in combination with venetoclax (Bcl-2 inhibitor) for 24&#x000a0;h and then we performed to CCK-8 assay and calculated the IC<sub>50</sub> values. A plot of the IC<sub>50</sub> values for each inhibitor appears on the axes; the solid line indicates additive effects, while the points represent concentrations inhibiting proliferation by 50%. Synergistic points are below the line, whereas antagonistic points are above it. <bold>(B)</bold> MOLM-13 cells (panel left) and THP-1 cells (panel right) were treated with 20(S)-PPD alone or in combination with the Bcl-2 inhibitor venetoclax for 8&#x000a0;h and then we performed to Annexin V/PI staining and flow cytometry analyses. **P &#x0003c; 0.01; ***P &#x0003c; 0.001 compared to the no drug treatment control, while ###, P &#x0003c; 0.001 compared to 20(S)-PPD-treated group. <bold>(C)</bold> PBMCs were treated with 40&#x000a0;&#x003bc;M 20(S)-PPD alone or in combination with venetoclax for 8&#x000a0;h and stained with annexin V-FITC/PI. **P &#x0003c; 0.01; ***P &#x0003c; 0.001 compared to the no drug treatment control, while ns, non-significant, compared to venetoclax-treated group. <bold>(D)</bold> MOLM-13 cells (panel left) and THP-1 cells (panel right) were treated with 20(S)-PPD alone or in combination with venetoclax for 8&#x000a0;h and then we performed to WB assay. Densitometry measurements are shown below the corresponding blots, normalized to &#x003b2;-actin and compared to the vehicle control group.</p></caption><graphic xlink:href="fphar-16-1530270-g005" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>4 Discussion</title><p>The main challenges in treating AML include patient tolerability, susceptibility to drug resistance, and high relapse rates, necessitating the development of novel therapeutic strategies (<xref rid="B21" ref-type="bibr">Limongello et al., 2021</xref>; <xref rid="B23" ref-type="bibr">Liu et al., 2022</xref>; <xref rid="B51" ref-type="bibr">Sugamori et al., 2022</xref>). 20(S)-PPD has demonstrated anti-tumor potential in various solid tumors (<xref rid="B62" ref-type="bibr">Zhu et al., 2011</xref>; <xref rid="B61" ref-type="bibr">Zhang et al., 2013</xref>; <xref rid="B2" ref-type="bibr">Ben-Eltriki et al., 2016</xref>; <xref rid="B57" ref-type="bibr">Zhang et al., 2018</xref>; <xref rid="B33" ref-type="bibr">Peng et al., 2019</xref>; <xref rid="B25" ref-type="bibr">Lu et al., 2020</xref>; <xref rid="B58" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B10" ref-type="bibr">Fu et al., 2022</xref>; <xref rid="B50" ref-type="bibr">Song et al., 2023</xref>). This study found that 20(S)-PPD inhibits AML cell proliferation and induces apoptosis (<xref rid="F1" ref-type="fig">Figures 1A&#x02013;D</xref>). Accumulating evidence suggests that 20(S)-PPD induces apoptosis via the intrinsic/mitochondrial pathway in several preclinical models of both solid tumors and hematological malignancies (<xref rid="B34" ref-type="bibr">Popovich and Kitts, 2002</xref>; <xref rid="B35" ref-type="bibr">2004</xref>; <xref rid="B28" ref-type="bibr">Ming et al., 2007</xref>). By silencing Bax and Bak, the central effectors of the intrinsic/mitochondrial apoptosis pathway, we demonstrated that 20(S)-PPD-induced apoptosis in AML cells is at least partially mediated through this pathway (<xref rid="F1" ref-type="fig">Figures 1F, G</xref>). Bcl-2 protein family that includes anti-apoptotic members like Bcl-2, MCL1, and Bcl-X<sub>L</sub>, as well as pro-apoptotic members such as BIM, Bax, and Bak, regulates mitochondrial apoptosis (<xref rid="B48" ref-type="bibr">Singh et al., 2019</xref>; <xref rid="B4" ref-type="bibr">Carneiro and El-Deiry, 2020</xref>). Our data indicate that 20(S)-PPD treatment downregulates the Bcl-X<sub>L</sub> and MCL-1 expression, while the levels of Bax, Bak, Bcl-2 and Bfl-1 remaind unchanged in three tested AML cells (<xref rid="F2" ref-type="fig">Figure 2</xref>). The expression of Bim exhibited a slight increase in THP-1 and MV4-11 cells, while it remained unchanged in MOLM-13 cells (<xref rid="F2" ref-type="fig">Figure 2</xref>), potentially attributable to the heterogeneity of AML cells.</p><p>To elucidate the role of Bcl-X<sub>L</sub> and MCL-1 in 20(S)-PPD-induced apoptosis, overexpression of Bcl-X<sub>L</sub> or MCL-1, coupled with the application of selective inhibitors targeting MCL-1 or Bcl-2, provided direct evidence that 20(S)-PPD induces apoptosis in AML cells by inhibiting Bcl-X<sub>L</sub> and MCL-1 proteins (<xref rid="F3" ref-type="fig">Figure 3</xref>). 20(S)-PPD decreased both mRNA and protein stability of Bcl-X<sub>L</sub> and MCL-1 in subsequent studies (<xref rid="F4" ref-type="fig">Figures 4A&#x02013;C</xref>). These findings indicate that the downregulation of Bcl-X<sub>L</sub> and MCL-1 levels induced by 20(S)-PPD may be achieved through the reduction of their gene expression and the acceleration of protein degradation. Furthermore, our virtual molecular docking analysis suggests that the acceleration of protein degradation by 20(S)-PPD may result from direct interactions between 20(S)-PPD and MCL-1/Bcl-X<sub>L</sub> molecules (<xref rid="F4" ref-type="fig">Figures 4D, E</xref>). Additionally, a recent study found that 20(S)-PPD induces apoptosis in AML cells by inhibiting the PI3K/AKT/mTOR pathway and the expression of the transcription factor c-Myc (<xref rid="B60" ref-type="bibr">Zhang et al., 2025</xref>). Given that the PI3K/AKT/mTOR pathway or c-Myc can regulate the expression of MCL-1 and/or Bcl-X<sub>L</sub>, the downregulation of MCL-1/Bcl-X<sub>L</sub> by 20(S)-PPD may be mediated by its inhibition of the PI3K/AKT/mTOR pathway or c-Myc expression (<xref rid="B38" ref-type="bibr">Rahmani et al., 2014</xref>; <xref rid="B16" ref-type="bibr">Jokinen and Koivunen, 2015</xref>; <xref rid="B13" ref-type="bibr">Hu et al., 2020</xref>). However, the exact molecular mechanisms still require further investigation.</p><p>It is well established that Bcl-X<sub>L</sub>, Bcl-2, and MCL-1 are aberrantly expressed in many cancer cell lines, enabling these cells to circumvent apoptosis (<xref rid="B5" ref-type="bibr">Carter et al., 2020</xref>). Several studies have demonstrated that MCL-1 and Bcl-2 are overexpressed frequently in AML cell lines, with high expression levels being associated with poor prognoses and resistance to chemotherapy (<xref rid="B8" ref-type="bibr">Delia et al., 1992</xref>; <xref rid="B9" ref-type="bibr">Fowler-Shorten et al., 2024</xref>). Through the Gene Expression Omnibus (GEO) database (GSE35008) and Cancer Genome Atlas (TCGA) database, we found that MCL-1 is upregulated in AML patients and negatively correlates with overall survival rates (<xref rid="s12" ref-type="sec">Supplementary Figures S1A&#x02013;C</xref>). Conversely, the GEO database (GSE35008) and TCGA database analysis indicated that Bcl-X<sub>L</sub> is downregulated (<xref rid="s12" ref-type="sec">Supplementary Figures S1A, B</xref>). The observation that low expression of Bcl-X<sub>L</sub> is positively correlated with overall survival rates in early-stage AML patients, but negatively correlated in later stages (<xref rid="s12" ref-type="sec">Supplementary Figure S1C</xref>), is noteworthy. A plausible explanation for this phenomenon is that early-stage AML cells depend on Bcl-X<sub>L</sub> for survival, whereas late-stage AML cells may rely on other Bcl-2 family members, such as Bcl-2 or MCL-1. This pattern is analogous to findings in T cell development, where early progenitor T cells require Bcl-X<sub>L</sub> for their development, while more mature T cells depend on Bcl-2 (<xref rid="B42" ref-type="bibr">Ryan et al., 2010</xref>; <xref rid="B48" ref-type="bibr">Singh et al., 2019</xref>).</p><p>A potent Bcl-2 inhibitor, venetoclax, has been approved by the FDA to treat patients with 17p deletions in chronic lymphocytic leukemia (CLL) (<xref rid="B27" ref-type="bibr">Merino et al., 2018</xref>; <xref rid="B40" ref-type="bibr">Roberts et al., 2021</xref>). As a monotherapy, venetoclax has only achieved a 19% overall response rate (<xref rid="B1" ref-type="bibr">Andreeff et al., 1999</xref>; <xref rid="B18" ref-type="bibr">Konopleva et al., 2016</xref>). The modest efficacy of venetoclax in AML patients is attributed to intrinsic drug resistance mechanisms. Specifically, the Bcl-X<sub>L</sub> and/or MCL-1 upregulation represents the primary mechanisms of resistance to venetoclax (<xref rid="B31" ref-type="bibr">Pan et al., 2014</xref>; <xref rid="B6" ref-type="bibr">Choudhary et al., 2015</xref>; <xref rid="B36" ref-type="bibr">Punnoose et al., 2016</xref>; <xref rid="B14" ref-type="bibr">Jayappa et al., 2017</xref>; <xref rid="B52" ref-type="bibr">Tahir et al., 2017</xref>; <xref rid="B12" ref-type="bibr">Haselager et al., 2020</xref>). Preclinical studies have demonstrated that the inhibition of Bcl-X<sub>L</sub> and/or MCL-1 exhibits significant anti-AML activity and enhances the sensitivity of venetoclax in AML treatment (<xref rid="B5" ref-type="bibr">Carter et al., 2020</xref>; <xref rid="B53" ref-type="bibr">Vanna et al., 2020</xref>). However, the clinical application of inhibitors targeting Bcl-X<sub>L</sub> or MCL-1 is constrained by issues of intolerance and potential toxicity. For instance, <italic>in vivo</italic> and <italic>in vitro</italic>, ABT-737 and ABT-263 have shown remarkable anti-tumor activity against various hematological malignancies through inhibition of Bcl-X<sub>L</sub>, Bcl-2, and Bcl-W. Nevertheless, their clinical development is hindered by associated platelet toxicity (<xref rid="B26" ref-type="bibr">Mason et al., 2007</xref>; <xref rid="B55" ref-type="bibr">Wilson et al., 2010</xref>; <xref rid="B39" ref-type="bibr">Roberts et al., 2016</xref>). MCL-1 inhibitors S63845 and AZD5991 exhibit poor tolerance due to their association with myelosuppression and potential cardiac toxicity, respectively (<xref rid="B3" ref-type="bibr">Brennan et al., 2018</xref>; <xref rid="B32" ref-type="bibr">Parrondo et al., 2022</xref>).</p><p>Several studies have indicated that high doses of 20(S)-PPD (100&#x000a0;mg/kg) do not induce weight loss or toxicity such as hepatotoxicity, nephrotoxicity, cardiotoxicity in mice (<xref rid="B57" ref-type="bibr">Zhang et al., 2018</xref>; <xref rid="B15" ref-type="bibr">Jo et al., 2021</xref>; <xref rid="B10" ref-type="bibr">Fu et al., 2022</xref>). These <italic>in vivo</italic> findings suggest that patients may exhibit improved tolerance to 20(S)-PPD. In this study, we observed that even at a concentration of 60&#x000a0;&#x003bc;M, 20(S)-PPD did not increase the proportion of Annexin V+ cells in normal PBMCs (<xref rid="F1" ref-type="fig">Figure 1E</xref>), suggesting a lack of toxicity to normal cells. Since 20(S)-PPD is a dual inhibitor of both Bcl-X<sub>L</sub> and MCL-1 and exhibits minimal toxicity, it suggests that the combination of 20(S)-PPD and venetoclax may be a potential strategy for treating AML. Indeed, our results demonstrates that 20(S)-PPD synergistically enhances the sensitivity of venetoclax against AML <italic>ex vivo</italic> models (<xref rid="F5" ref-type="fig">Figure 5</xref>). However, further investigations are required to assess the efficacy and toxicity of 20(S)-PPD alone or in combination with venetoclax in AML animal models or clinical trials.</p><p>In conclusion, our results indicate that 20(S)-PPD inhibits proliferation and induces apoptosis in AML cells <italic>in vitro</italic>. Mechanistically, we demonstrate that 20(S)-PPD induces apoptosis in AML cells by down-regulating the protein and transcript levels of Bcl-X<sub>L</sub> and MCL-1 (<xref rid="F6" ref-type="fig">Figure 6</xref>). Furthermore, our data indicated that 20(S)-PPD synergistically enhances the anti-leukemic activity of venetoclax <italic>in vitro</italic>. The current study suggests that the continued development of 20(S)-PPD as a therapeutic drug for AML would be advantageous.</p><fig position="float" id="F6"><label>FIGURE 6</label><caption><p>Schematic representation of anti-leukemic mechanism of 20(S)-PPD in AML cells. 20(S)-PPD downregulates Bcl-X<sub>L</sub> and MCL-1, thereby promoting the oligomerization of Bax/Bak, leading to changes in MOMP, release of cytochrome C, activation of caspase, and ultimately inducing apoptosis. MOMP, mitochondrial membrane permeability.</p></caption><graphic xlink:href="fphar-16-1530270-g006" position="float"/></fig></sec></body><back><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref rid="s12" ref-type="sec">Supplementary Material</xref>.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>MX: Data curation, Writing &#x02013; original draft. FH: Formal Analysis, Funding acquisition, Writing &#x02013; review and editing. SW: Methodology, Writing &#x02013; review and editing. ZQ: Data curation, Writing &#x02013; review and editing. JL: Validation, Writing &#x02013; review and editing. SC: Funding acquisition, Supervision, Writing &#x02013; review and editing. FF: Funding acquisition, Writing &#x02013; review and editing. YZ: Funding acquisition, Project administration, Writing &#x02013; review and editing. CH: Conceptualization, Writing &#x02013; original draft.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1530270/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2025.1530270/full#supplementary-material</ext-link>
</p><supplementary-material position="float" content-type="local-data"><label>SUPPLEMENTARY FIGURE S1</label><caption><p>The correlation between the gene expression of Bcl-X<sub>L</sub> and MCL-1 in AML clinical patient sample and overall survival. <bold>(A)</bold> GEO database (GSE35008) analyzed, the gene expression of MCL-1 and Bcl-X<sub>L</sub> (known as BCL2L1) in AML clinical patient sample and normal sample. G1, AML group; G2, healthy group. **P &#x0003c; 0.01, compared to normal sample; ns, non-significance. <bold>(B)</bold> TCGA database analyzed, the gene expression of MCL-1 and Bcl-X<sub>L</sub> in AML clinical patient sample and normal sample. TPM, transcripts per million. *P &#x0003c; 0.05, compared to normal sample. <bold>(C)</bold> The association between MCL-1 or Bcl-X<sub>L</sub> expression and overall survival percent in patients with AML.</p></caption></supplementary-material><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Image1.jpg"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreeff</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Konopleva</surname><given-names>M.</given-names></name><name><surname>Estrov</surname><given-names>Z.</given-names></name><name><surname>Snell</surname><given-names>V. E.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid</article-title>. <source>Leukemia</source>
<volume>13</volume> (<issue>11</issue>), <fpage>1881</fpage>&#x02013;<lpage>1892</lpage>. <pub-id pub-id-type="doi">10.1038/sj.leu.2401573</pub-id>
<pub-id pub-id-type="pmid">10557066</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben-Eltriki</surname><given-names>M.</given-names></name><name><surname>Deb</surname><given-names>S.</given-names></name><name><surname>Adomat</surname><given-names>H.</given-names></name><name><surname>Tomlinson Guns</surname><given-names>E. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Calcitriol and 20(S)-protopanaxadiol synergistically inhibit growth and induce apoptosis in human prostate cancer cells</article-title>. <source>J. Steroid Biochem. Mol. Biol.</source>
<volume>158</volume>, <fpage>207</fpage>&#x02013;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2015.12.002</pub-id>
<pub-id pub-id-type="pmid">26709138</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brennan</surname><given-names>M. S.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name><name><surname>Tai</surname><given-names>L.</given-names></name><name><surname>Lessene</surname><given-names>G.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name><name><surname>Dewson</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use</article-title>. <source>Blood</source>
<volume>132</volume> (<issue>15</issue>), <fpage>1573</fpage>&#x02013;<lpage>1583</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2018-06-859405</pub-id>
<pub-id pub-id-type="pmid">30139826</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>B. A.</given-names></name><name><surname>El-Deiry</surname><given-names>W. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Targeting apoptosis in cancer therapy</article-title>. <source>Nat. Rev. Clin. Oncol.</source>
<volume>17</volume> (<issue>7</issue>), <fpage>395</fpage>&#x02013;<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-020-0341-y</pub-id>
<pub-id pub-id-type="pmid">32203277</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carter</surname><given-names>J. L.</given-names></name><name><surname>Hege</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Kalpage</surname><given-names>H. A.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Edwards</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy</article-title>. <source>Signal Transduct. Target Ther.</source>
<volume>5</volume> (<issue>1</issue>), <fpage>288</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-020-00361-x</pub-id>
<pub-id pub-id-type="pmid">33335095</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choudhary</surname><given-names>G. S.</given-names></name><name><surname>Al-Harbi</surname><given-names>S.</given-names></name><name><surname>Mazumder</surname><given-names>S.</given-names></name><name><surname>Hill</surname><given-names>B. T.</given-names></name><name><surname>Smith</surname><given-names>M. R.</given-names></name><name><surname>Bodo</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies</article-title>. <source>Cell Death Dis.</source>
<volume>6</volume> (<issue>1</issue>), <fpage>e1593</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2014.525</pub-id>
<pub-id pub-id-type="pmid">25590803</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Czabotar</surname><given-names>P. E.</given-names></name><name><surname>Garcia-Saez</surname><given-names>A. J.</given-names></name></person-group> (<year>2023</year>). <article-title>Mechanisms of BCL-2 family proteins in mitochondrial apoptosis</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>24</volume> (<issue>10</issue>), <fpage>732</fpage>&#x02013;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-023-00629-4</pub-id>
<pub-id pub-id-type="pmid">37438560</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delia</surname><given-names>D.</given-names></name><name><surname>Aiello</surname><given-names>A.</given-names></name><name><surname>Soligo</surname><given-names>D.</given-names></name><name><surname>Fontanella</surname><given-names>E.</given-names></name><name><surname>Melani</surname><given-names>C.</given-names></name><name><surname>Pezzella</surname><given-names>F.</given-names></name><etal/></person-group> (<year>1992</year>). <article-title>bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells</article-title>. <source>Blood</source>
<volume>79</volume> (<issue>5</issue>), <fpage>1291</fpage>&#x02013;<lpage>1298</lpage>. <pub-id pub-id-type="doi">10.1182/blood.v79.5.1291.bloodjournal7951291</pub-id>
<pub-id pub-id-type="pmid">1536952</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fowler-Shorten</surname><given-names>D. J.</given-names></name><name><surname>Hellmich</surname><given-names>C.</given-names></name><name><surname>Markham</surname><given-names>M.</given-names></name><name><surname>Bowles</surname><given-names>K. M.</given-names></name><name><surname>Rushworth</surname><given-names>S. A.</given-names></name></person-group> (<year>2024</year>). <article-title>BCL-2 inhibition in haematological malignancies: clinical application and complications</article-title>. <source>Blood Rev.</source>
<volume>65</volume>, <fpage>101195</fpage>. <pub-id pub-id-type="doi">10.1016/j.blre.2024.101195</pub-id>
<pub-id pub-id-type="pmid">38523032</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Improved therapeutic efficacy of CBD with good tolerance in the treatment of breast cancer through nanoencapsulation and in combination with 20(S)-Protopanaxadiol (PPD)</article-title>. <source>Pharmaceutics</source>
<volume>14</volume> (<issue>8</issue>), <fpage>1533</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14081533</pub-id>
<pub-id pub-id-type="pmid">35893789</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guerra</surname><given-names>V. A.</given-names></name><name><surname>DiNardo</surname><given-names>C.</given-names></name><name><surname>Konopleva</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Venetoclax-based therapies for acute myeloid leukemia</article-title>. <source>Best. Pract. Res. Clin. Haematol.</source>
<volume>32</volume> (<issue>2</issue>), <fpage>145</fpage>&#x02013;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1016/j.beha.2019.05.008</pub-id>
<pub-id pub-id-type="pmid">31203996</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haselager</surname><given-names>M. V.</given-names></name><name><surname>Kielbassa</surname><given-names>K.</given-names></name><name><surname>Ter Burg</surname><given-names>J.</given-names></name><name><surname>Bax</surname><given-names>D. J. C.</given-names></name><name><surname>Fernandes</surname><given-names>S. M.</given-names></name><name><surname>Borst</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL</article-title>. <source>Blood</source>
<volume>136</volume> (<issue>25</issue>), <fpage>2918</fpage>&#x02013;<lpage>2926</lpage>. <pub-id pub-id-type="doi">10.1182/blood.2019004326</pub-id>
<pub-id pub-id-type="pmid">32603412</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Bai</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: antitumour activity and molecular mechanism of action</article-title>. <source>J. Cell Mol. Med.</source>
<volume>24</volume> (<issue>13</issue>), <fpage>7239</fpage>&#x02013;<lpage>7253</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.15281</pub-id>
<pub-id pub-id-type="pmid">32459381</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jayappa</surname><given-names>K. D.</given-names></name><name><surname>Portell</surname><given-names>C. A.</given-names></name><name><surname>Gordon</surname><given-names>V. L.</given-names></name><name><surname>Capaldo</surname><given-names>B. J.</given-names></name><name><surname>Bekiranov</surname><given-names>S.</given-names></name><name><surname>Axelrod</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Microenvironmental agonists generate <italic>de novo</italic> phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL</article-title>. <source>Blood Adv.</source>
<volume>1</volume> (<issue>14</issue>), <fpage>933</fpage>&#x02013;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1182/bloodadvances.2016004176</pub-id>
<pub-id pub-id-type="pmid">29034364</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jo</surname><given-names>H.</given-names></name><name><surname>Jang</surname><given-names>D.</given-names></name><name><surname>Park</surname><given-names>S. K.</given-names></name><name><surname>Lee</surname><given-names>M. G.</given-names></name><name><surname>Cha</surname><given-names>B.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Ginsenoside 20(S)-protopanaxadiol induces cell death in human endometrial cancer cells via apoptosis</article-title>. <source>J. Ginseng Res.</source>
<volume>45</volume> (<issue>1</issue>), <fpage>126</fpage>&#x02013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgr.2020.02.002</pub-id>
<pub-id pub-id-type="pmid">33437164</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jokinen</surname><given-names>E.</given-names></name><name><surname>Koivunen</surname><given-names>J. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage</article-title>. <source>Int. J. Oncol.</source>
<volume>47</volume> (<issue>3</issue>), <fpage>1103</fpage>&#x02013;<lpage>1110</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2015.3071</pub-id>
<pub-id pub-id-type="pmid">26135106</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khwaja</surname><given-names>A.</given-names></name><name><surname>Bjorkholm</surname><given-names>M.</given-names></name><name><surname>Gale</surname><given-names>R. E.</given-names></name><name><surname>Levine</surname><given-names>R. L.</given-names></name><name><surname>Jordan</surname><given-names>C. T.</given-names></name><name><surname>Ehninger</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Acute myeloid leukaemia</article-title>. <source>Nat. Rev. Dis. Prim.</source>
<volume>2</volume>, <fpage>16010</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2016.10</pub-id>
<pub-id pub-id-type="pmid">27159408</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konopleva</surname><given-names>M.</given-names></name><name><surname>Pollyea</surname><given-names>D. A.</given-names></name><name><surname>Potluri</surname><given-names>J.</given-names></name><name><surname>Chyla</surname><given-names>B.</given-names></name><name><surname>Hogdal</surname><given-names>L.</given-names></name><name><surname>Busman</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia</article-title>. <source>Cancer Discov.</source>
<volume>6</volume> (<issue>10</issue>), <fpage>1106</fpage>&#x02013;<lpage>1117</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0313</pub-id>
<pub-id pub-id-type="pmid">27520294</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>C.</given-names></name><name><surname>Doucette</surname><given-names>K.</given-names></name><name><surname>Norsworthy</surname><given-names>K.</given-names></name></person-group> (<year>2019</year>). <article-title>Recent drug approvals for acute myeloid leukemia</article-title>. <source>J. Hematol. Oncol.</source>
<volume>12</volume> (<issue>1</issue>), <fpage>100</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-019-0774-x</pub-id>
<pub-id pub-id-type="pmid">31533852</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lichtman</surname><given-names>M. A.</given-names></name></person-group> (<year>2013</year>). <article-title>A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3</article-title>. <source>Blood Cells Mol. Dis.</source>
<volume>50</volume> (<issue>2</issue>), <fpage>119</fpage>&#x02013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcmd.2012.10.005</pub-id>
<pub-id pub-id-type="pmid">23154039</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Limongello</surname><given-names>R.</given-names></name><name><surname>Marra</surname><given-names>A.</given-names></name><name><surname>Mancusi</surname><given-names>A.</given-names></name><name><surname>Bonato</surname><given-names>S.</given-names></name><name><surname>Hoxha</surname><given-names>E.</given-names></name><name><surname>Ruggeri</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Novel immune cell-based therapies to eradicate high-risk acute myeloid leukemia</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>, <fpage>695051</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.695051</pub-id>
<pub-id pub-id-type="pmid">34413848</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>Emerging agents and regimens for AML</article-title>. <source>J. Hematol. Oncol.</source>
<volume>14</volume> (<issue>1</issue>), <fpage>49</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-021-01062-w</pub-id>
<pub-id pub-id-type="pmid">33757574</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Hussain</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>Q.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax</article-title>. <source>Exp. Cell Res.</source>
<volume>417</volume> (<issue>2</issue>), <fpage>113192</fpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2022.113192</pub-id>
<pub-id pub-id-type="pmid">35568072</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy</article-title>. <source>Pharmacol. Res.</source>
<volume>161</volume>, <fpage>105263</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.105263</pub-id>
<pub-id pub-id-type="pmid">33127555</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Fu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>20(S)-Protopanaxadiol inhibits epithelial-mesenchymal transition by promoting retinoid X receptor alpha in human colorectal carcinoma cells</article-title>. <source>J. Cell Mol. Med.</source>
<volume>24</volume> (<issue>24</issue>), <fpage>14349</fpage>&#x02013;<lpage>14365</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.16054</pub-id>
<pub-id pub-id-type="pmid">33128348</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mason</surname><given-names>K. D.</given-names></name><name><surname>Carpinelli</surname><given-names>M. R.</given-names></name><name><surname>Fletcher</surname><given-names>J. I.</given-names></name><name><surname>Collinge</surname><given-names>J. E.</given-names></name><name><surname>Hilton</surname><given-names>A. A.</given-names></name><name><surname>Ellis</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Programmed anuclear cell death delimits platelet life span</article-title>. <source>Cell</source>
<volume>128</volume> (<issue>6</issue>), <fpage>1173</fpage>&#x02013;<lpage>1186</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2007.01.037</pub-id>
<pub-id pub-id-type="pmid">17382885</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merino</surname><given-names>D.</given-names></name><name><surname>Kelly</surname><given-names>G. L.</given-names></name><name><surname>Lessene</surname><given-names>G.</given-names></name><name><surname>Wei</surname><given-names>A. H.</given-names></name><name><surname>Roberts</surname><given-names>A. W.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>BH3-Mimetic drugs: blazing the trail for new cancer medicines</article-title>. <source>Cancer Cell</source>
<volume>34</volume> (<issue>6</issue>), <fpage>879</fpage>&#x02013;<lpage>891</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2018.11.004</pub-id>
<pub-id pub-id-type="pmid">30537511</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ming</surname><given-names>Y. L.</given-names></name><name><surname>Song</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>L. H.</given-names></name><name><surname>Zheng</surname><given-names>Z. Z.</given-names></name><name><surname>Chen</surname><given-names>Z. Y.</given-names></name><name><surname>Ouyang</surname><given-names>G. L.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Anti-proliferation and apoptosis induced by a novel intestinal metabolite of ginseng saponin in human hepatocellular carcinoma cells</article-title>. <source>Cell Biol. Int.</source>
<volume>31</volume> (<issue>10</issue>), <fpage>1265</fpage>&#x02013;<lpage>1273</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellbi.2007.05.005</pub-id>
<pub-id pub-id-type="pmid">17587608</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nwosu</surname><given-names>G. O.</given-names></name><name><surname>Ross</surname><given-names>D. M.</given-names></name><name><surname>Powell</surname><given-names>J. A.</given-names></name><name><surname>Pitson</surname><given-names>S. M.</given-names></name></person-group> (<year>2024</year>). <article-title>Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia</article-title>. <source>Cell Death Dis.</source>
<volume>15</volume> (<issue>6</issue>), <fpage>413</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-024-06810-7</pub-id>
<pub-id pub-id-type="pmid">38866760</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ong</surname><given-names>F.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Konopleva</surname><given-names>M. Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Venetoclax resistance: mechanistic insights and future strategies</article-title>. <source>Cancer Drug Resist</source>
<volume>5</volume> (<issue>2</issue>), <fpage>380</fpage>&#x02013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.20517/cdr.2021.125</pub-id>
<pub-id pub-id-type="pmid">35800373</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>R.</given-names></name><name><surname>Hogdal</surname><given-names>L. J.</given-names></name><name><surname>Benito</surname><given-names>J. M.</given-names></name><name><surname>Bucci</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Borthakur</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia</article-title>. <source>Cancer Discov.</source>
<volume>4</volume> (<issue>3</issue>), <fpage>362</fpage>&#x02013;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0609</pub-id>
<pub-id pub-id-type="pmid">24346116</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parrondo</surname><given-names>R. D.</given-names></name><name><surname>Paulus</surname><given-names>A.</given-names></name><name><surname>Ailawadhi</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Updates in the use of BCL-2-family small molecule inhibitors for the treatment of relapsed/refractory multiple myeloma</article-title>. <source>Cancers (Basel)</source>
<volume>14</volume> (<issue>14</issue>), <fpage>3330</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14143330</pub-id>
<pub-id pub-id-type="pmid">35884390</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>He</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Hou</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis <italic>in vivo</italic> by targeting EGFR-mediated MAPK pathway</article-title>. <source>Pharmacol. Res.</source>
<volume>142</volume>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2019.02.003</pub-id>
<pub-id pub-id-type="pmid">30735802</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Popovich</surname><given-names>D. G.</given-names></name><name><surname>Kitts</surname><given-names>D. D.</given-names></name></person-group> (<year>2002</year>). <article-title>Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line</article-title>. <source>Arch. Biochem. Biophys.</source>
<volume>406</volume> (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/s0003-9861(02)00398-3</pub-id>
<pub-id pub-id-type="pmid">12234484</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Popovich</surname><given-names>D. G.</given-names></name><name><surname>Kitts</surname><given-names>D. D.</given-names></name></person-group> (<year>2004</year>). <article-title>Mechanistic studies on protopanaxadiol, Rh2, and ginseng (Panax quinquefolius) extract induced cytotoxicity in intestinal Caco-2 cells</article-title>. <source>J. Biochem. Mol. Toxicol.</source>
<volume>18</volume> (<issue>3</issue>), <fpage>143</fpage>&#x02013;<lpage>149</lpage>. <pub-id pub-id-type="doi">10.1002/jbt.20019</pub-id>
<pub-id pub-id-type="pmid">15252870</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Punnoose</surname><given-names>E. A.</given-names></name><name><surname>Leverson</surname><given-names>J. D.</given-names></name><name><surname>Peale</surname><given-names>F.</given-names></name><name><surname>Boghaert</surname><given-names>E. R.</given-names></name><name><surname>Belmont</surname><given-names>L. D.</given-names></name><name><surname>Tan</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models</article-title>. <source>Mol. Cancer Ther.</source>
<volume>15</volume> (<issue>5</issue>), <fpage>1132</fpage>&#x02013;<lpage>1144</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0730</pub-id>
<pub-id pub-id-type="pmid">26939706</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer</article-title>. <source>Biosci. Trends</source>
<volume>9</volume> (<issue>1</issue>), <fpage>16</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2015.01019</pub-id>
<pub-id pub-id-type="pmid">25787906</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rahmani</surname><given-names>M.</given-names></name><name><surname>Aust</surname><given-names>M. M.</given-names></name><name><surname>Benson</surname><given-names>E. C.</given-names></name><name><surname>Wallace</surname><given-names>L.</given-names></name><name><surname>Friedberg</surname><given-names>J.</given-names></name><name><surname>Grant</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Clin. Cancer Res.</source>
<volume>20</volume> (<issue>18</issue>), <fpage>4849</fpage>&#x02013;<lpage>4860</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-14-0034</pub-id>
<pub-id pub-id-type="pmid">25070836</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A. W.</given-names></name><name><surname>Davids</surname><given-names>M. S.</given-names></name><name><surname>Pagel</surname><given-names>J. M.</given-names></name><name><surname>Kahl</surname><given-names>B. S.</given-names></name><name><surname>Puvvada</surname><given-names>S. D.</given-names></name><name><surname>Gerecitano</surname><given-names>J. F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia</article-title>. <source>N. Engl. J. Med.</source>
<volume>374</volume> (<issue>4</issue>), <fpage>311</fpage>&#x02013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1513257</pub-id>
<pub-id pub-id-type="pmid">26639348</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A. W.</given-names></name><name><surname>Wei</surname><given-names>A. H.</given-names></name><name><surname>Huang</surname><given-names>D. C. S.</given-names></name></person-group> (<year>2021</year>). <article-title>BCL2 and MCL1 inhibitors for hematologic malignancies</article-title>. <source>Blood</source>
<volume>138</volume> (<issue>13</issue>), <fpage>1120</fpage>&#x02013;<lpage>1136</lpage>. <pub-id pub-id-type="doi">10.1182/blood.2020006785</pub-id>
<pub-id pub-id-type="pmid">34320168</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rooswinkel</surname><given-names>R. W.</given-names></name><name><surname>van de Kooij</surname><given-names>B.</given-names></name><name><surname>de Vries</surname><given-names>E.</given-names></name><name><surname>Paauwe</surname><given-names>M.</given-names></name><name><surname>Braster</surname><given-names>R.</given-names></name><name><surname>Verheij</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity</article-title>. <source>Blood</source>
<volume>123</volume> (<issue>18</issue>), <fpage>2806</fpage>&#x02013;<lpage>2815</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-08-519470</pub-id>
<pub-id pub-id-type="pmid">24622325</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryan</surname><given-names>J. A.</given-names></name><name><surname>Brunelle</surname><given-names>J. K.</given-names></name><name><surname>Letai</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>107</volume> (<issue>29</issue>), <fpage>12895</fpage>&#x02013;<lpage>12900</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0914878107</pub-id>
<pub-id pub-id-type="pmid">20615979</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shamas-Din</surname><given-names>A.</given-names></name><name><surname>Kale</surname><given-names>J.</given-names></name><name><surname>Leber</surname><given-names>B.</given-names></name><name><surname>Andrews</surname><given-names>D. W.</given-names></name></person-group> (<year>2013</year>). <article-title>Mechanisms of action of Bcl-2 family proteins</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source>
<volume>5</volume> (<issue>4</issue>), <fpage>a008714</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a008714</pub-id>
<pub-id pub-id-type="pmid">23545417</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>Z. Y.</given-names></name><name><surname>Zeng</surname><given-names>J. Z.</given-names></name><name><surname>Wong</surname><given-names>A. S. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Chemical structures and pharmacological profiles of ginseng saponins</article-title>. <source>Molecules</source>
<volume>24</volume> (<issue>13</issue>), <fpage>2443</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24132443</pub-id>
<pub-id pub-id-type="pmid">31277214</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimada</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Hematological malignancies and molecular targeting therapy</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>862</volume>, <fpage>172641</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172641</pub-id>
<pub-id pub-id-type="pmid">31493406</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimony</surname><given-names>S.</given-names></name><name><surname>Stahl</surname><given-names>M.</given-names></name><name><surname>Stone</surname><given-names>R. M.</given-names></name></person-group> (<year>2023</year>). <article-title>Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management</article-title>. <source>Am. J. Hematol.</source>
<volume>98</volume> (<issue>3</issue>), <fpage>502</fpage>&#x02013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1002/ajh.26822</pub-id>
<pub-id pub-id-type="pmid">36594187</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimony</surname><given-names>S.</given-names></name><name><surname>Stone</surname><given-names>R. M.</given-names></name><name><surname>Stahl</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes</article-title>. <source>Curr. Opin. Hematol.</source>
<volume>29</volume> (<issue>2</issue>), <fpage>63</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1097/MOH.0000000000000698</pub-id>
<pub-id pub-id-type="pmid">34966123</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Letai</surname><given-names>A.</given-names></name><name><surname>Sarosiek</surname><given-names>K.</given-names></name></person-group> (<year>2019</year>). <article-title>Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>20</volume> (<issue>3</issue>), <fpage>175</fpage>&#x02013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-018-0089-8</pub-id>
<pub-id pub-id-type="pmid">30655609</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siveen</surname><given-names>K. S.</given-names></name><name><surname>Uddin</surname><given-names>S.</given-names></name><name><surname>Mohammad</surname><given-names>R. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Targeting acute myeloid leukemia stem cell signaling by natural products</article-title>. <source>Mol. Cancer</source>
<volume>16</volume> (<issue>1</issue>), <fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-016-0571-x</pub-id>
<pub-id pub-id-type="pmid">28137265</pub-id>
</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Shen</surname><given-names>T.</given-names></name><name><surname>Kim</surname><given-names>H. G.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Cho</surname><given-names>J. Y.</given-names></name></person-group> (<year>2023</year>). <article-title>20(S)-Protopanaxadiol from panax ginseng induces apoptosis and autophagy in gastric cancer cells by inhibiting src</article-title>. <source>Am. J. Chin. Med.</source>
<volume>51</volume> (<issue>1</issue>), <fpage>205</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1142/S0192415X2350012X</pub-id>
<pub-id pub-id-type="pmid">36408728</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sugamori</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>T.</given-names></name><name><surname>Mitomi</surname><given-names>T.</given-names></name><name><surname>Yamagishi</surname><given-names>C.</given-names></name></person-group> (<year>2022</year>). <article-title>Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan</article-title>. <source>Jpn. J. Clin. Oncol.</source>
<volume>52</volume> (<issue>7</issue>), <fpage>766</fpage>&#x02013;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1093/jjco/hyac069</pub-id>
<pub-id pub-id-type="pmid">35523692</pub-id>
</mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tahir</surname><given-names>S. K.</given-names></name><name><surname>Smith</surname><given-names>M. L.</given-names></name><name><surname>Hessler</surname><given-names>P.</given-names></name><name><surname>Rapp</surname><given-names>L. R.</given-names></name><name><surname>Idler</surname><given-names>K. B.</given-names></name><name><surname>Park</surname><given-names>C. H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Potential mechanisms of resistance to venetoclax and strategies to circumvent it</article-title>. <source>BMC Cancer</source>
<volume>17</volume> (<issue>1</issue>), <fpage>399</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-017-3383-5</pub-id>
<pub-id pub-id-type="pmid">28578655</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vanna</surname><given-names>R.</given-names></name><name><surname>Morasso</surname><given-names>C.</given-names></name><name><surname>Marcinno</surname><given-names>B.</given-names></name><name><surname>Piccotti</surname><given-names>F.</given-names></name><name><surname>Torti</surname><given-names>E.</given-names></name><name><surname>Altamura</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Raman spectroscopy reveals that biochemical composition of breast microcalcifications correlates with histopathologic features</article-title>. <source>Cancer Res.</source>
<volume>80</volume> (<issue>8</issue>), <fpage>1762</fpage>&#x02013;<lpage>1772</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3204</pub-id>
<pub-id pub-id-type="pmid">32094303</pub-id>
</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>A. H.</given-names></name><name><surname>Roberts</surname><given-names>A. W.</given-names></name></person-group> (<year>2023</year>). <article-title>BCL2 inhibition: a new paradigm for the treatment of AML and beyond</article-title>. <source>Hemasphere</source>
<volume>7</volume> (<issue>6</issue>), <fpage>e912</fpage>. <pub-id pub-id-type="doi">10.1097/HS9.0000000000000912</pub-id>
<pub-id pub-id-type="pmid">37304937</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilson</surname><given-names>W. H.</given-names></name><name><surname>O'Connor</surname><given-names>O. A.</given-names></name><name><surname>Czuczman</surname><given-names>M. S.</given-names></name><name><surname>LaCasce</surname><given-names>A. S.</given-names></name><name><surname>Gerecitano</surname><given-names>J. F.</given-names></name><name><surname>Leonard</surname><given-names>J. P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity</article-title>. <source>Lancet Oncol.</source>
<volume>11</volume> (<issue>12</issue>), <fpage>1149</fpage>&#x02013;<lpage>1159</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(10)70261-8</pub-id>
<pub-id pub-id-type="pmid">21094089</pub-id>
</mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>A. S.</given-names></name><name><surname>Che</surname><given-names>C. M.</given-names></name><name><surname>Leung</surname><given-names>K. W.</given-names></name></person-group> (<year>2015</year>). <article-title>Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview</article-title>. <source>Nat. Prod. Rep.</source>
<volume>32</volume> (<issue>2</issue>), <fpage>256</fpage>&#x02013;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1039/c4np00080c</pub-id>
<pub-id pub-id-type="pmid">25347695</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>H. L.</given-names></name><name><surname>Wang</surname><given-names>Y. C.</given-names></name><name><surname>Lu</surname><given-names>Z. Y.</given-names></name><name><surname>Yu</surname><given-names>X. F.</given-names></name><name><surname>Sui</surname><given-names>D. Y.</given-names></name></person-group> (<year>2018</year>). <article-title>20(S)-Protopanaxadiol-Induced apoptosis in MCF-7 breast cancer cell line through the inhibition of PI3K/AKT/mTOR signaling pathway</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>19</volume> (<issue>4</issue>), <fpage>1053</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19041053</pub-id>
<pub-id pub-id-type="pmid">29614812</pub-id>
</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Zuo</surname><given-names>P.</given-names></name><name><surname>Jing</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>20(S)-Protopanaxadiol blocks cell cycle progression by targeting epidermal growth factor receptor</article-title>. <source>Food Chem. Toxicol.</source>
<volume>135</volume>, <fpage>111017</fpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2019.111017</pub-id>
<pub-id pub-id-type="pmid">31805304</pub-id>
</mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Qiu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Cai</surname><given-names>P.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>The positive role of traditional Chinese medicine as an adjunctive therapy for cancer</article-title>. <source>Biosci. Trends</source>
<volume>15</volume> (<issue>5</issue>), <fpage>283</fpage>&#x02013;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2021.01318</pub-id>
<pub-id pub-id-type="pmid">34421064</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>The antitumor effects and apoptotic mechanism of 20(S)-Protopanaxadiol in acute myeloid leukemia</article-title>. <source>J. Ginseng Res.</source>
<pub-id pub-id-type="doi">10.1016/j.jgr.2025.03.006</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. L.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>H. L.</given-names></name><name><surname>Yu</surname><given-names>X. F.</given-names></name><name><surname>Qu</surname><given-names>S. C.</given-names></name><name><surname>Sui</surname><given-names>D. Y.</given-names></name></person-group> (<year>2013</year>). <article-title>20(S)-protopanaxadiol triggers mitochondrial-mediated apoptosis in human lung adenocarcinoma A549 cells via inhibiting the PI3K/Akt signaling pathway</article-title>. <source>Am. J. Chin. Med.</source>
<volume>41</volume> (<issue>5</issue>), <fpage>1137</fpage>&#x02013;<lpage>1152</lpage>. <pub-id pub-id-type="doi">10.1142/S0192415X13500778</pub-id>
<pub-id pub-id-type="pmid">24117074</pub-id>
</mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G. Y.</given-names></name><name><surname>Li</surname><given-names>Y. W.</given-names></name><name><surname>Tse</surname><given-names>A. K.</given-names></name><name><surname>Hau</surname><given-names>D. K.</given-names></name><name><surname>Leung</surname><given-names>C. H.</given-names></name><name><surname>Yu</surname><given-names>Z. L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>20(S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>668</volume> (<issue>1-2</issue>), <fpage>88</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2011.06.008</pub-id>
<pub-id pub-id-type="pmid">21703260</pub-id>
</mixed-citation></ref></ref-list></back></article>